X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA CIPLA SHASUN PHARMA/
CIPLA
 
P/E (TTM) x 123.9 44.8 276.5% View Chart
P/BV x 8.5 3.7 231.0% View Chart
Dividend Yield % 0.2 0.3 67.1%  

Financials

 SHASUN PHARMA   CIPLA
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
CIPLA
Mar-17
SHASUN PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs94622 15.1%   
Low Rs46458 9.9%   
Sales per share (Unadj.) Rs214.2181.9 117.8%  
Earnings per share (Unadj.) Rs5.312.9 41.5%  
Cash flow per share (Unadj.) Rs15.829.3 54.0%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %1.40.4 386.3%  
Book value per share (Unadj.) Rs53.3155.7 34.3%  
Shares outstanding (eoy) m56.62804.51 7.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.33.0 11.0%   
Avg P/E ratio x13.142.0 31.2%  
P/CF ratio (eoy) x4.418.4 24.0%  
Price / Book Value ratio x1.33.5 37.8%  
Dividend payout %18.715.5 120.6%   
Avg Mkt Cap Rs m3,958434,516 0.9%   
No. of employees `000NA23.0 0.0%   
Total wages/salary Rs m2,16426,338 8.2%   
Avg. sales/employee Rs ThNM6,349.1-  
Avg. wages/employee Rs ThNM1,143.0-  
Avg. net profit/employee Rs ThNM449.3-  
INCOME DATA
Net Sales Rs m12,127146,302 8.3%  
Other income Rs m2292,287 10.0%   
Total revenues Rs m12,356148,589 8.3%   
Gross profit Rs m1,00924,758 4.1%  
Depreciation Rs m59413,229 4.5%   
Interest Rs m4151,594 26.0%   
Profit before tax Rs m23012,222 1.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.4%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-731,798 -4.0%   
Profit after tax Rs m30210,354 2.9%  
Gross profit margin %8.316.9 49.2%  
Effective tax rate %-31.714.7 -215.2%   
Net profit margin %2.57.1 35.2%  
BALANCE SHEET DATA
Current assets Rs m6,88487,370 7.9%   
Current liabilities Rs m8,45633,081 25.6%   
Net working cap to sales %-13.037.1 -34.9%  
Current ratio x0.82.6 30.8%  
Inventory Days Days6287 70.9%  
Debtors Days Days10862 172.6%  
Net fixed assets Rs m4,970111,567 4.5%   
Share capital Rs m1131,609 7.0%   
"Free" reserves Rs m2,875123,645 2.3%   
Net worth Rs m3,020125,254 2.4%   
Long term debt Rs m1,81736,454 5.0%   
Total assets Rs m13,347209,532 6.4%  
Interest coverage x1.68.7 17.9%   
Debt to equity ratio x0.60.3 206.8%  
Sales to assets ratio x0.90.7 130.1%   
Return on assets %5.45.7 94.2%  
Return on equity %10.08.3 121.0%  
Return on capital %13.38.5 156.7%  
Exports to sales %46.434.2 135.5%   
Imports to sales %14.28.3 170.8%   
Exports (fob) Rs m5,62250,050 11.2%   
Imports (cif) Rs m1,72812,203 14.2%   
Fx inflow Rs m5,84351,066 11.4%   
Fx outflow Rs m2,17317,678 12.3%   
Net fx Rs m3,66933,388 11.0%   
CASH FLOW
From Operations Rs m39823,824 1.7%  
From Investments Rs m-1,635-13,127 12.5%  
From Financial Activity Rs m1,309-13,239 -9.9%  
Net Cashflow Rs m71-2,478 -2.9%  

Share Holding

Indian Promoters % 39.2 16.0 245.0%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 3.6 12.2 29.5%  
FIIs % 17.6 23.7 74.3%  
ADR/GDR % 0.0 1.1 -  
Free float % 39.6 26.2 151.1%  
Shareholders   20,750 161,166 12.9%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   DR. REDDYS LAB  IPCA LABS  JUBILANT LIFE SCIENCES  VENUS REMEDIES  PIRAMAL ENTERPRISES  

Compare SHASUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Coal India Stock Rallies 4.2%(Closing)

Indian share markets finished some selling pressure in the final hour of trade to finish flat amid weak European markets.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS